HC Wainwright reaffirmed their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $105.00 price objective on the stock. Other analysts have also issued reports about the company. Wedbush boosted their price objective on Praxis Precision […]
Related Keywords
, Acuta Capital Partners , Praxis Precision Medicines Inc , Citigroup Inc , Silverarc Capital Management , Jefferies Financial Group , Asset Management Inc , Praxis Precision Medicines , Free Report , Financial Group , Precision Medicines , Get Free Report , Capital Partners , Capital Management , Management Inc , Praxis Precision Medicines Daily , Nasdaq Prax , Aprax , Medical , Reiterated Rating , Hc Wainwright ,
comparemela.com © 2020. All Rights Reserved.